Premenstrual Syndrome Treatment Market reached USD 1,367 million in 2023 and is estimated to reach USD 1,829 million by 2031 | Exclusive Data Like Latest M & A, Regulatory Approvals, FDA Approvals, Latest Investments, Reimbursements

Premenstrual Syndrome Treatment Market size was valued USD 1,367 million in 2022 and is estimated to reach USD 1,829 million by 2031, growing at a CAGR of 4.1% during the forecast period (2024-2031).

DataM Intelligence has published a new research report on "Premenstrual Syndrome Treatment Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/premenstrual-syndrome-treatment-market?rk

Key Players:

Bayer AG, Eli Lilly and Company, GlaxoSmithKline Plc, Pfizer Inc., H. Lundbeck A/S, Pfizer Inc., Asarina Pharma AB, Chattem, Inc. (Sanofi), Dekk-Tec, Pherin Pharmaceuticals, Novartis International AG.

Key Development:

United States: Recent Industry Developments

✅ In September 2025, AbbVie Inc. announced new data from its ELARIA clinical program evaluating Orilissa® (elagolix) for moderate-to-severe premenstrual symptoms linked to hormonal imbalance. Results showed significant reduction in irritability, mood swings, and physical discomfort compared to placebo.

✅ In August 2025, Pfizer Inc. initiated a Phase 2 trial for its novel serotonin-norepinephrine reuptake inhibitor (SNRI) aimed at managing emotional and physical symptoms of PMS and PMDD (Premenstrual Dysphoric Disorder). The drug is designed to provide faster onset of action than existing SSRIs.

✅ In June 2025, Bayer AG (U.S. division) expanded its women's health portfolio with an upgraded Yaz® (drospirenone/ethinyl estradiol) oral contraceptive line incorporating AI-based adherence tracking for improved patient compliance.

✅ In May 2025, Theralogix LLC launched a clinically tested vitamin and mineral formulation targeting mild PMS symptoms, including bloating and fatigue. The supplement leverages evidence-based combinations of calcium, magnesium, and vitamin B6.

Japan: Recent Industry Developments

✅ In September 2025, Takeda Pharmaceutical Company Ltd. began Phase 1 trials for a neuroactive peptide modulator intended to balance serotonin and GABA signaling in women with severe PMS and PMDD, addressing mood-related symptoms through a novel mechanism.

✅ In July 2025, Shionogi & Co., Ltd. announced research collaboration with Kyoto University to study hormonal gene expression patterns linked to PMS, aiming to identify biomarkers for personalized treatment strategies.

✅ In June 2025, Otsuka Pharmaceutical Co., Ltd. launched a digital women's health platform integrating symptom tracking, hormonal data, and AI-based risk assessment to help clinicians optimize PMS treatment plans.

✅ In May 2025, Taisho Pharmaceutical Holdings Co., Ltd. introduced an OTC herbal combination therapy derived from Kampo medicine for mild PMS relief, combining chasteberry and angelica root extracts.

Growth Forecast Projected:

The Global Premenstrual Syndrome Treatment Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Premenstrual Syndrome Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=premenstrual-syndrome-treatment-market?rk

Key Segments:

➠ By Drug Class: Analgesics, Antidepressants, Oral Contraceptives, Ovarian Suppression Agents, Gonadotropin-releasing hormone (GnRH) Analogues, Estrogen-only patches & implants, Selective serotonin reuptake inhibitors (SSRIs), Others.

➠ By Distribution Channel: Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Providers, Others.

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/premenstrual-syndrome-treatment-market?rk

Request 2 Days Free Trials with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.